Benzinga · Sep 24, 2026
Scinai Files Prospectus For Resale Of Up To 2,706,450 ADS By YA II PN
https://www.sec.gov/Archives/edgar/data/1611747/000121390026103067/ea0306554-f1_scinai.htm
SC
NASDAQ · SCNI
Scinai Immunotherapeutics Ltd.
Healthcare · Biotechnology
$1.18
Down-$0.03 (-2.48%)
Updated Oct 11, 2026, 12:59 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.63M
- P/E ratio
- -0.14
- Dividend yield
- 0.00%
- 52-week range
- $0.21 – $3.58
- Volume
- 20.35K
- Avg. volume
- 74.12K
Price performance · SCNI
SCNI price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
SCNI closed at $1.18 after 20 trading sessions, down 51.64% for the selected period.
- Last close
- $1.18
- Period change
- -51.64%
- Period low
- $1.13
- Period high
- $2.44
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $1.22 | $1.23 | $1.18 | $1.18 | 20.35K |
| Oct 8, 2026 | $1.11 | $1.23 | $1.06 | $1.21 | 90.57K |
| Oct 7, 2026 | $1.20 | $1.23 | $1.12 | $1.13 | 40.44K |
| Oct 6, 2026 | $1.2628 | $1.29 | $1.22 | $1.22 | 44.3K |
| Oct 5, 2026 | $1.33 | $1.3624 | $1.26 | $1.26 | 42.26K |
| Oct 2, 2026 | $1.3022 | $1.37 | $1.30 | $1.33 | 22.17K |
| Oct 1, 2026 | $1.39 | $1.4499 | $1.27 | $1.31 | 43.75K |
| Sep 30, 2026 | $1.3601 | $1.42 | $1.32 | $1.42 | 80.13K |
| Sep 29, 2026 | $1.50 | $1.50 | $1.35 | $1.41 | 98.63K |
| Sep 28, 2026 | $1.55 | $1.57 | $1.43 | $1.47 | 67.36K |
| Sep 25, 2026 | $1.715 | $1.73 | $1.55 | $1.55 | 120.81K |
| Sep 24, 2026 | $1.91 | $1.9389 | $1.81 | $1.86 | 165.67K |
| Sep 23, 2026 | $1.76 | $2.08 | $1.69 | $1.98 | 517.38K |
| Sep 22, 2026 | $1.61 | $1.9327 | $1.57 | $1.91 | 661.23K |
| Sep 21, 2026 | $1.71 | $1.83 | $1.57 | $1.69 | 16.25M |
| Sep 18, 2026 | $1.60 | $1.77 | $1.50 | $1.56 | 216.93K |
| Sep 17, 2026 | $1.44 | $1.73 | $1.4345 | $1.62 | 408.1K |
| Sep 16, 2026 | $1.43 | $1.56 | $1.43 | $1.52 | 395.05K |
| Sep 15, 2026 | $1.84 | $1.88 | $1.50 | $1.54 | 1.43M |
| Sep 14, 2026 | $2.33 | $2.67 | $2.21 | $2.44 | 41.06M |
Latest SCNI news
The latest Smart Investors Daily articles mentioning SCNI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SCNI research
Overview
Company profile and research snapshot.
Company profile
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Sep 21, 2026
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced that it has received written notification from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now
Benzinga · Sep 21, 2026
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock moved upwards
Benzinga · Sep 15, 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences (NASDAQ:JUNS) stock
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
